Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Studies in vivo and in healthy volunteers support investigation of AT-2101

March 29, 2007

Positive phase IIa results for DIO-902 in type 2 diabetes

March 28, 2007

Merck & Co. and Schering-Plough to develop new cholesterol lowering product

March 28, 2007

Vardenafil studies presented at European Association of Urology congress

March 28, 2007

Preclinical and phase I data on activity of AT-1001 presented

March 28, 2007

Januvia approved in E.U. for type 2 diabetes

March 27, 2007

New treatment options for metabolic disorders are disclosed in patent literature

March 27, 2007

Pain Therapeutics in-licenses new technology for treatment of hemophilia

March 27, 2007

ProAlgaZyme to be studied in metabolic syndrome patients

March 26, 2007

GlycoPEG-GCSF begins second phase I trial

March 23, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...